法律意见书 广东华商（长沙）律师事务所 关于湖南方盛制药股份有限公司 2022年股权激励计划部分限制性股票 回购注销实施相关事项的 回购注销实施相关事项的 二〇二五年五月 法律意见书 广东华商（长沙）律师事务所（以下简称"本所"）接受湖南方盛制药股份 有限公司（以下简称"公司"或"方盛制药"）的委托，作为公司2022年限制性 股票激励计划（以下简称"本次激励计划"）项目的特聘专项法律顾问，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）及中国证券监督管理委员会（以下简称"中国证监 会"）发布的《上市公司股权激励管理办法》（以下简称"《管理办法》"）等 相关法律、法规和规范性文件以及《湖南方盛制药股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，按照律师行业公认的业务标准、道德规范和 勤勉尽责精神，对公司回购注销部分激励对象已获授限制性股票实施（以下简称 "本次回购注销"）相关事项出具本法律意见书。 广东华商（长沙）律师事务所 法律意见书 法律意见书 致：湖南方盛制药股份有限公司 关于湖南方盛制药股份有限公司 2022年股权激励计划部分限制 ...

2024 年年度股东大会 会议资料 中国湖南 长沙 2025 年 5 月 20 日 大会主持人：董事长周晓莉女士 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 2024 年年度股东大会会议议程 会议时间：2025 年 5 月 20 日下午 14:30 会议地点：公司办公大楼一楼会议室（一）（长沙市国家高新技术产业开发 区嘉运路 299 号） 会议召集人：公司董事会 | 2024 | | 年年度股东大会会议议程 | 3 | | --- | --- | --- | --- | | 2024 | | 年年度股东大会会议须知 | 5 | | 议案 1：公司 2024 | | 年度董事会工作报告 | 6 | | 议案 2：公司 2024 | | 年度监事会工作报告 | 10 | | 议案 3：公司 2024 | 年度财务决算报告及 2025 | 年财务预算报告 15 | | | 议案 4：关于公司 2024 | | 年年度报告及其摘要的议案 21 | | | 议案 5：关于公司 2024 | | 年度利润分配方案的预案 22 | | | | 控制审计机构的议案 ...

湖南方盛制药股份有限公司 HUNANFANGSHENGPHARMACEUTICALCO.,LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-053 湖南方盛制药股份有限公司 关于控股子公司股东结构变更及相关事项的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提醒： 公司及芙雅生物（合并称"甲方"）与香港同盛、同田生物及邓力先生、 邓秋云先生（合并称"乙方"）就香港同盛减资芙雅生物及相关合作事项达成一 揽子交易，本次乙方减资，除退还其出资的无形资产外，甲方放弃设备与债权及 现金补偿合计 1,017 万元（以账面价值计算），具体情况如下： 乙方：通过减资的方式退出对芙雅生物的全部投资（分配资产为此前增资时 价值 3,000 万元的无形资产，账面价值 2,050 万元）；放弃芙雅生物应付未付的 135.20 万元货款、设备维修金及其所产生的违约金； 甲方：放弃根据《购销合同》已付货款 1,334.80 万元（账面价值约 943 万元）， 乙方可以取回设备，终止《购销合同》；放弃因相关协议及款项 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-052 特此公告 湖南方盛制药股份有限公司监事会 2025年5月8日 第 1 页，共 1 页 第六届监事会 2025 年第三次临时会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）第六届监 事会 2025 年第三次临时会议于 2025 年 5 月 7 日下午 16:00 在办 公大楼一楼会议室（一）召开。会议通知已于 2025 年 4 月 30 日 以书面形式告知全体监事。本次会议由公司监事会主席肖满女士 召集并主持，会议应出席监事 3 人，实际出席监事 3 人。公司董 事会秘书列席了本次会议。本次会议召开符合法律、法规、规章 及《公司章程》的有关规定，会议合法、有效。会议审议并通过 了《关于控股子公司股东结构变更及相关事项的议案》： 本次公司及控股子公司与香港同盛实业有限公司、邓力先生、 邓秋云先生及关 ...

本次公司及控股子公司与香港同盛实业有限公司、邓力先生、邓 秋云先生及关联方上海同田生物技术有限公司签订《协议书》符合公 司及云南芙雅生物科技有限公司实际情况和发展需要，不存在损害中 小股东利益的情形，符合有关法律法规、规范性文件和《公司章程》 等的有关规定。 综上，我们同意《关于控股子公司股东结构变更及相关事项的议 案》，并将该议案提交公司第六届董事会 2025 年第三次临时会议审议。 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 第六届董事会独立董事专门会议决议 （2025 年第一次临时会议） 湖南方盛制药股份有限公司（以下简称"公司"）第六届董事会 独立董事专门会议 2025 年第一次临时会议于 2025 年 5 月 6 日以通讯 表决的方式召开。会议通知及会议材料已于 2025 年 4 月 30 日以电子 邮件、微信、电话等方式通知全体独立董事。本次会议由独立董事袁 雄先生召集并主持，会议应出席独立董事 3 人，实际出席独立董事 3 人。本次会议参与表决人数及召集、召开程序符合《公司法》和《公 司章程》的有关规定，会议 ...

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its pediatric cough granules have successfully completed a Phase II clinical trial for treating acute bronchitis in adults, indicating potential for market expansion and increased revenue [1][2][6]. Group 1: Clinical Trial Information - The pediatric cough granules received clinical approval for adult acute bronchitis on March 11, 2022, with a total R&D expenditure of approximately 21.65 million RMB [1]. - The Phase II clinical trial involved 330 participants, randomized into high-dose (30g/day), low-dose (15g/day), and placebo groups, with results showing significant efficacy in reducing cough severity and improving related symptoms [6][7]. - The trial demonstrated that both high and low doses were more effective than the placebo, with no serious adverse events reported [6][7]. Group 2: Market Position and Financial Performance - The pediatric cough granules are the company's proprietary product and have generated nearly 90 million RMB in sales in 2024, marking a 73% increase [3][11]. - The market for cough and bronchitis medications includes competitors such as Kyoto Nishikyo's syrup and Taiji Group's products, with significant sales figures reported for these alternatives [4][3]. - The overall sales of cough and phlegm-relieving traditional Chinese medicine exceeded 15.8 billion RMB in the first half of 2024 across various healthcare settings [4]. Group 3: Future Outlook and Strategic Plans - The company plans to leverage the successful clinical trial results to enhance its product portfolio and expand market reach, focusing on innovative drug development [11][15]. - The strategic focus includes optimizing resource allocation and increasing the proportion of innovative drug revenue, which currently stands at 11% [11]. - Future growth is anticipated through the development of a diverse product matrix and improved operational efficiency, aiming for sustainable growth over the next 3-5 years [15].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2024 is in line with expectations, with total revenue reaching 1.777 billion yuan, a year-on-year increase of 9.15%, and a net profit attributable to shareholders of 255.22 million yuan, up 36.61% [8] - The company has a diverse product matrix that supports stable performance, with significant growth in cardiovascular and anti-infection medications, while respiratory medications faced some pressure [8] - The dual strategy of "innovative drugs + centralized procurement drugs" is showing significant results, with key products like Xuanqi Jianguo tablets and pediatric cough granules experiencing substantial sales growth [8] Financial Summary - Total revenue forecast for 2024 is 1.777 billion yuan, with a projected growth rate of 9.15% [9] - Net profit attributable to shareholders is expected to be 255.22 million yuan in 2024, with a growth rate of 36.61% [9] - The earnings per share (EPS) is projected to be 0.58 yuan for 2024, with a price-to-earnings (P/E) ratio of 16.71 [9] - The company's gross margin is expected to improve to 71.85% in 2024, reflecting a 3.75 percentage point increase [8] - The net profit margin is projected to rise to 14.06% in 2024, an increase of 3.03 percentage points [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in 2024 is in line with expectations, with total revenue reaching 1.777 billion yuan, a year-on-year increase of 9.15%, and a net profit attributable to shareholders of 255.22 million yuan, up 36.61% year-on-year [8] - The company has a diverse product matrix that supports stable performance, with significant growth in cardiovascular and anti-infection medications, while respiratory medications faced some pressure [8] - The dual strategy of "innovative drugs + centralized procurement drugs" is showing significant results, with key products like Xuanqi Jianguo tablets and pediatric cough granules experiencing substantial sales growth [8] Financial Summary - Total revenue forecast for 2024 is 1.777 billion yuan, with a projected growth rate of 9.15% [9] - The net profit attributable to shareholders is expected to be 255.22 million yuan in 2024, with a growth rate of 36.61% [9] - The earnings per share (EPS) is projected to be 0.58 yuan for 2024, with a price-to-earnings (P/E) ratio of 16.71 [9] - The gross profit margin for 2024 is expected to be 71.85%, reflecting a year-on-year increase of 3.75 percentage points [9] - The net profit margin is projected to improve to 14.06% in 2024, up 3.03 percentage points from the previous year [9]

Core Insights - The report highlights that the inbound economy may boost China's GDP by approximately 0.2 percentage points in 2025, driven by policy changes aimed at optimizing the outbound tax refund system and increasing inbound consumption [5][6][7] - The report provides a detailed analysis of various industries and companies, indicating a mixed performance across sectors, with some companies showing strong growth while others face challenges [3][4] Industry Overview - **Chemical Industry**: Huafeng Chemical (002064.SZ) reported Q1 performance exceeding expectations, with revenue of 6.314 billion yuan, a year-on-year decrease of 5.15%, and a net profit of 504 million yuan, down 26.21% year-on-year, but a significant increase of 145.60% quarter-on-quarter [28][29] - **Coal Mining**: Lu'an Environmental Energy (601699.SH) faced a decline in both volume and price, leading to a projected annual revenue of 35.85 billion yuan, down 16.9% year-on-year, and a net profit of 2.45 billion yuan, down 69.1% year-on-year [32][33] - **Textiles and Apparel**: Mousse Co., Ltd. (001323.SZ) reported a Q1 revenue of 1.12 billion yuan, a decrease of 6.7% year-on-year, with expectations for recovery following government subsidies [54][55] - **Home Appliances**: Dechang Co., Ltd. (605555.SH) achieved a Q1 revenue of 1 billion yuan, up 21.33% year-on-year, with a focus on expanding production capacity in Southeast Asia [40][41] Company-Specific Insights - **Huafeng Chemical**: The company is consolidating its position in the polyurethane industry through vertical mergers and acquisitions, maintaining a "buy" rating with projected net profits of 2.474 billion, 3.110 billion, and 3.822 billion yuan for 2025-2027 [28][30] - **Lu'an Environmental Energy**: The company is expected to see a rebound in coal prices, with a focus on capacity growth and price elasticity, maintaining a "buy" rating despite recent performance challenges [32][34] - **Mousse Co., Ltd.**: The company is enhancing its multi-channel and multi-category market layout, with a projected net profit of 799 million, 872 million, and 956 million yuan for 2025-2027 [54][55] - **Dechang Co., Ltd.**: The company is expanding its overseas production capacity and expects significant growth in its automotive motor segment, maintaining a "buy" rating [40][41]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-051 湖南方盛制药股份有限公司 关于2024年度暨2025年第一季度业绩暨现金分红 说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"方盛制药"或"公 司"）于 2025 年 4 月 29 日（星期二）上午 9:00—10:00 以网络 互动方式，通过上证路演中心召开 2024 年度暨 2025 年第一季度 业绩暨现金分红说明会，就公司 2024 年年度及 2025 年第一季度 经营业绩情况，以及其他投资者普遍关心的问题与投资者进行交 流与沟通。现将有关情况公告如下： 一、本次说明会召开情况 出席本次网上业绩说明会的公司人员为：董事长兼总经理周 晓莉女士、独立董事袁雄先生、财务总监曹湘琦女士、董事会秘 书何仕先生。 二、投资者提出的主要问题及公司回复情况 公司就投资者在本次说明会上提出的问题进行了回复， ...